e-ISSN:2320-1215 p-ISSN: 2322-0112

Reach Us +447482878454
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Rohit Mathur

Rohit Mathur

DR. Rohit Mathur

Department of Lymphoma/Myeloma

M.D. Anderson Cancer Center

USA

Biography

M.D. Anderson Cancer Center, Houston Houston, TX Postdoctoral Research Fellow; Advisor: Felipe Samaniego 2011-2015 Targeting relapse and chemoresistance in Non-Hodgkin Lymphoma Diffuse large B-cell lymphoma  Epigenetic therapy: Demethylase inhibitors for improving treatment in diffuse large B-cell lymphoma (DLBCL). Methylation pattern increases with aggressiveness of tumor, therefore we have started investigating demethylases in regulation of DLBCL. Our current study suggests that JMJD3 could be a potential target for drug development in DLBCL. Mantle cell lymphoma  Stem cell signaling in lymphoma stem cells. We have found Wnt as an important pathway differentially up-regulated in Mantle cell lymphoma-initiating cells (MCL-ICs), which can be used to target MCL-ICs. Further, we are working to find unique markers on MCL-ICs.  Role of Long non coding RNA in chemoresistance of mantle cell lymphoma. We have elucidated function of long-non-coding RNAs in MCL-ICs. We have found that Fas-As1 expression could be responsible for resistance to ibrutinib.

Research Interest

Nuclear Medicine, cancer, lymphoma,